The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

EXCLUSIVE: Poppy Liu (Hacks, Space Cadet) and Chris Bauer (Fellow Travelers, The Wire) have joined the cast of Netflix’s ...

Had the Dateline NBC vet not gone public with her decision to vacate her Today spot, Hoda Kotb might have been the one ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...

Meta CEO Mark Zuckerberg, who has been undergoing a style evolution, just showed off a Porsche Cayenne that was retrofitted ...

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...

Filming is underway on Netflix's adaptation of Alice Feeney's His & Hers starring Tessa Thompson and Jon Bernthal.

Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli ...